Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
NB

NASDAQ · NBIX

Neurocrine Biosciences, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$146.10

Down-$0.28 (-0.19%)

Updated Nov 2, 2026, 8:28 AM

SID Score

5.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
15.39B
P/E ratio
35.94
Dividend yield
0.00%
52-week range
$122.14 – $186.12
Volume
1.32M
Avg. volume
958.25K

Price performance · NBIX

NBIX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

NBIX closed at $146.10 after 20 trading sessions, up 1.31% for the selected period.

Last close
$146.10
Period change
+1.31%
Period low
$135.13
Period high
$146.38
Daily close
View OHLC price history
NBIX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$147.13$149.25$145.22$146.101.32M
Oct 29, 2026$146.57$147.17$145.37$146.38831.12K
Oct 28, 2026$144.56$145.98$143.00$145.531.09M
Oct 27, 2026$145.01$146.59$143.91$146.001.18M
Oct 26, 2026$143.99$146.00$142.335$145.871.29M
Oct 23, 2026$142.735$143.83$140.895$142.701.03M
Oct 22, 2026$141.62$143.83$140.75$143.291.24M
Oct 21, 2026$141.38$142.77$140.835$141.31815.51K
Oct 20, 2026$138.51$142.09$137.90$142.001.26M
Oct 19, 2026$136.335$137.53$135.005$136.981.05M
Oct 16, 2026$137.86$138.1994$135.55$135.711.13M
Oct 15, 2026$137.26$138.23$135.55$136.951.38M
Oct 14, 2026$133.94$136.5699$132.25$135.911.51M
Oct 13, 2026$139.60$139.925$134.89$135.131.57M
Oct 12, 2026$142.37$143.625$140.89$141.371.09M
Oct 9, 2026$141.33$143.55$140.02$142.441.02M
Oct 8, 2026$142.88$143.02$140.34$141.251.24M
Oct 7, 2026$145.33$145.88$143.21$143.471.14M
Oct 6, 2026$145.56$145.77$141.39$145.511.45M
Oct 5, 2026$142.94$146.915$142.48$144.211.75M

Latest NBIX news

The latest Smart Investors Daily articles mentioning NBIX.

Stock researchCompany · Overview

NBIX research

Overview

Company profile and research snapshot.

Company profile

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$172.36
Implied upside
—
Analysts
35
NBIX recent ratings
DateFirmRatingTarget
Oct 16, 2026NeedhamBuy—
Oct 12, 2026BMO CapitalMarket Perform—
Sep 29, 2026UBSBuy—
Sep 11, 2026Morgan StanleyEqual-Weight—
Sep 8, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 30, 2026

Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of educational resources designed to help healthcare providers strengthen their understanding of classic congenital adrenal hyperplasia. The offerings include bootCAHmp®, an interactive, educational course that builds foundational clinical knowledge, and DiscoverCAH™, a virtual patient case experience that enables healthcare providers to apply their knowledge of the condition through realistic clinical decision-making scenari

Yahoo · Oct 30, 2026

Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter 2026

Tokyo, Japan and Cambridge, UK, 30 October 2026 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter ended 30 September 2026. The full report can be found here. Chris Cargill, President and CEO of Nxera, commented: “During the third quarter of FY2026, we continued to build on the progress made in the first half, focusing on growing our business and enhancing the value of our pipeline. In Japan

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By